A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

NCT05043402 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: navicixizumab
DEVICE: Xerna™ TME Panel

Sponsor

OncXerna Theraputics, Inc.